Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.30 EUR
Change Today +0.52 / 10.90%
Volume 0.0
2VS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

verastem inc (2VS) Snapshot

Open
€4.88
Previous Close
€4.78
Day High
€5.31
Day Low
€4.86
52 Week High
03/20/15 - €11.47
52 Week Low
08/27/15 - €4.23
Market Cap
195.5M
Average Volume 10 Days
72.5
EPS TTM
--
Shares Outstanding
36.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERASTEM INC (2VS)

verastem inc (2VS) Related Bloomberg News

View More Bloomberg News

verastem inc (2VS) Related Businessweek News

No Related Businessweek News Found

verastem inc (2VS) Details

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs). The company’s programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. Its lead FAK inhibitor, VS-6063, is in a registration-directed trial in patients with malignant pleural mesothelioma; a Phase Ib trial in combination with weekly paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; and a Phase II trial preceding surgery in mesothelioma, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. The company is also developing FAK inhibitor, VS-4718, and dual mTORC1/2 and PI3K inhibitor VS-5584 that are in Phase I clinical trials in patients with advanced cancers. Its product candidates target CSCs, which have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. The company has license agreement with Whitehead Institute for Biomedical Research; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is based in Needham, Massachusetts.

47 Employees
Last Reported Date: 03/10/15
Founded in 2010

verastem inc (2VS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $504.6K
Co-Founder and Executive Chairman
Total Annual Compensation: --
Chief Operating Officer
Total Annual Compensation: $363.1K
Senior Advisor
Total Annual Compensation: $388.9K
Compensation as of Fiscal Year 2014.

verastem inc (2VS) Key Developments

Verastem, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Verastem, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $15,462,000, net loss of $15,377,000 or $0.42 per basic and diluted share against loss from operations of $13,087,000, net loss of $13,022,000 or $0.51 per basic and diluted share for the same period a year ago. The company used $12.0 million for operating activities in the second quarter ended June 30, 2015. For the six months, the company reported loss from operations of $30,704,000, net loss of $30,557,000 or $0.87 per basic and diluted share against loss from operations of $26,221,000, net loss of $26,084,000 or $1.02 per basic and diluted share for the same period a year ago.

Verastem, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM

Verastem, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Robert Forrester, Chief Executive Officer, President and Director.

Verastem Announces Executive Changes, Effective July 1, 2015

Verastem, Inc. announced that Joanna Horobin, Chief Medical Officer (CMO), will transition to the role of Senior Advisor. In conjunction with this transition, the company also announced that Lou Vaickus will be named Interim CMO. These changes will become effective on July 1, 2015. Dr. Vaickus brings over 30 years of product development and commercialization experience to Verastem. In her new role, Dr. Horobin will focus primarily on identifying new opportunities to expand the development of Verastem’s pipeline programs with leading physicians globally. Prior to joining Verastem, Dr. Vaickus recently completed a 17-month appointment as interim CMO of InVivo Therapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2VS:GR €5.30 EUR +0.52

2VS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2VS.
View Industry Companies
 

Industry Analysis

2VS

Industry Average

Valuation 2VS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERASTEM INC, please visit www.verastem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.